HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

farglitazar

a non-thiazolidinedione insulin sensitiser and PPARgamma agonist

Also Known As:

GI 2570; GI 262570; GI-2570; GI-262570; GI2570; GI262570

Networked: 7 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - farglitazar: 7
Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Cyclic Amino Acids: 3
    - Aromatic Amino Acids: 467
      - Tyrosine: 10509
        farglitazar: 7

Experts

1.	Goodman, Zachary: 4 articles (01/2022 - 04/2010)
2.	Patel, Keyur: 4 articles (01/2022 - 04/2010)
3.	Karsdal, Morten A: 3 articles (01/2022 - 12/2016)
4.	Leeming, Diana J: 3 articles (01/2022 - 12/2016)
5.	Nielsen, Mette J: 2 articles (01/2022 - 01/2019)
6.	Schuppan, Detlef: 2 articles (01/2019 - 12/2016)
7.	Gardner, Stephen: 2 articles (12/2016 - 04/2010)
8.	Brown, Kathleen K: 2 articles (03/2006 - 08/2005)
9.	Bay-Jensen, Anne-Christine: 1 article (01/2022)
10.	Castañé, Helena: 1 article (01/2022)

Related Diseases

1.	Fibrosis (Cirrhosis) 04/01/2010 - "Patients with fibrosis of Ishak stages 2-4 (n = 265), based on analysis of liver biopsy samples, were randomly assigned to groups given once-daily doses of 0.5 mg farglitazar, 1.0 mg farglitazar, or placebo for 52 weeks; repeat liver biopsy samples were then obtained. " 04/01/2010 - "In patients with chronic hepatitis C and moderate fibrosis, 52 weeks of treatment with farglitazar does not affect stellate cell activation or fibrosis (measured by morphometry or comparison of paired biopsy specimens)." 12/01/2016 - "In the farglitazar study, a predefined cutoff value for Pro-C3 as a selection criterion led to the identification of subjects who 1) progressed by histological scores and 2) responded to therapy, as documented by attenuated fibrosis in liver biopsies. " 01/01/2022 - "A potential fibrosis resolution marker, CTX-III, was measured in two clinical cohorts of patients with obesity-associated non-alcoholic fatty liver disease undergoing bariatric surgery or hepatitis C virus infection from a clinical trial study evaluating the anti-fibrotic effect of farglitazar. "
2.	Hepatitis C 01/01/2019 - "Plasma samples from patients with moderate-stage hepatitis C receiving placebo treatment in a phase II trial of the peroxisome proliferator-activated receptor agonist farglitazar were included. " 12/01/2016 - "Samples from a phase II antifibrotic trial of the glitazone farglitazar in patients with advanced hepatitis C, with matched follow-up liver biopsies, and from a phase III study of balaglitazone in patients with late-stage Type 2 diabetes (BALLET study) were analyzed for serological Pro-C3 levels in conjunction with other disease parameters. "
3.	Type 2 Diabetes Mellitus (MODY) 12/01/2016 - "Samples from a phase II antifibrotic trial of the glitazone farglitazar in patients with advanced hepatitis C, with matched follow-up liver biopsies, and from a phase III study of balaglitazone in patients with late-stage Type 2 diabetes (BALLET study) were analyzed for serological Pro-C3 levels in conjunction with other disease parameters. " 12/01/2007 - "This study used DNA samples collected from type 2 diabetes phase III clinical trials of the PPARgamma agonist farglitazar (administered alone or in combination with insulin or glyburide) and investigated oedema reported as an adverse event as phenotype. "
4.	Infections 04/01/2010 - "Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection." 01/01/2022 - "A potential fibrosis resolution marker, CTX-III, was measured in two clinical cohorts of patients with obesity-associated non-alcoholic fatty liver disease undergoing bariatric surgery or hepatitis C virus infection from a clinical trial study evaluating the anti-fibrotic effect of farglitazar. "
5.	Non-alcoholic Fatty Liver Disease 01/01/2022 - "A potential fibrosis resolution marker, CTX-III, was measured in two clinical cohorts of patients with obesity-associated non-alcoholic fatty liver disease undergoing bariatric surgery or hepatitis C virus infection from a clinical trial study evaluating the anti-fibrotic effect of farglitazar. "

Related Drugs and Biologics

1.	PPAR gamma
2.	Peroxisome Proliferator-Activated Receptors (PPAR)
3.	Insulin (Novolin)
4.	Glyburide (Glibenclamide)
5.	DNA (Deoxyribonucleic Acid)
6.	Complement C3 (C3 Complement)
7.	balaglitazone
8.	Adiponectin

Related Therapies and Procedures

1.	Bariatric Surgery
2.	Therapeutics